Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine

Annals of Allergy, Asthma and Immunology

Volumn 91, Issue 2, 2003, Pages 205-211

  Berger, William E ^a   White, Martha V ^b  

^a Southern California Research   (United States)

^b Institute for Asthma and Allergy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZELASTINE; DESLORATADINE; LORATADINE; PLACEBO;

ADOLESCENT; ADULT; AGED; ALLERGIC RHINITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NASAL PRURITUS; NOSE CONGESTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0042739149     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62179-5     Document Type: Article

References (24)

1. Inoue Y. Basic studies on antiallergy drug, 4-(p-chlorobenzyl)-2[N-methylperhydroazepinyl-(4)]-1-(2H)-phthalazinone hydrochloride (azelastine). Nichi Idaishi. 1983;50:65-72.
2. Zechel HJ, Brock N, Lenke D, Achterrath-Tuckermann U. Pharmacological and toxicological properties of azelastine, a novel antiallergic agent. Arzneimittelforschung. 1981;31:1184-1193.
3. 4 formation and histamine secretion by azelastine: implication for its mechanism of action. Int Arch Allergy Appl Immunol. 1989;90:67-70.
4. Hamasaki Y, Shafigeh M, Yamamoto S, et al. Inhibition of leukotriene synthesis by azelastine. Ann Allergy Asthma Immunol. 1996;76:469-475.
5. 4 release and production by bronchial asthmatic eosinophils. Respir Res. 1990;9:206-212.
6. Shin MH, Baroody F, Proud D, Kagey-Sobotka A, Lichtenstein LM, Naclerio RM. The effect of azelastine on the early allergic response. Clin Exp Allergy. 1992;22:289-295.
7. Shinoda M, Watanabe N, Suko T, Mogi G, Takeyama M. Effects of antiallergic drugs on substance P (SP) and vasoactive intestinal peptide (VIP) in nasal secretions. Am J Rhinol. 1997;11:237-241.
8. Nieber K, Baumgarten C, Rathsack R, et al. Effect of azelastine on substance P content in bronchoalveolar and nasal lavage fluids of patients with allergic asthma. Clin Exp Allergy. 1993;23:69-71.
9. Ueta E, Osaki T, Yoneda K, Yamamoto T. Contrasting influence of peplomycin and azelastine hydrochloride (Azeptin) on reactive oxygen generation in polymorphonuclear leukocytes, cytokine generation in lymphocytes, and collagen synthesis in fibroblasts. Cancer Chemother Pharmacol. 1995;35:230-236.
10. Ito H, Nakamura Y, Takagi S, Sakai K. Effects of azelastine on the level of serum interleukin-4 and soluble CD23 antigen in the treatment of nasal allergy. Arzneimittelforschung. 1998;48:1143-1147.
11. Ciprandi G, Pronzato C, Passalacqua G, et al. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity. J Allergy Clin Immunol. 1996;98:1088-1096.
12. Ratner PH, Findlay SR, Hampel F, van Bavel J, Widlitz MD, Freitag JJ. A double-blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis. J Allergy Clin Immunol. 1994;94:818-825.
13. Storms WW, Pearlman DS, Chervinsky P, et al. Effectiveness of azelastine nasal solution in seasonal allergic rhinitis. Ear Nose Throat J. 1994;73:382-386, 392-394.
14. Weiler JM, Meltzer EO, Benson PM, Weiler K, Widlitz MD, Freitag J. A dose-ranging study of the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis with an acute model. J Allergy Clin Immunol. 1994;94:972-980.
15. Meltzer EO, Weiler JM, Dockhorn RJ, Widlitz MD, Freitag JJ. Azelastine nasal spray in the management of seasonal allergic rhinitis. Ann Allergy. 1994;72:354-359.
16. Banov CH, Lieberman P. Vasomotor Rhinitis Study Groups. Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis. Ann Allergy Asthma Immunol. 2001;86:28-35.
17. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on practice parameters in allergy, asthma and immunology. Ann Allergy Asthma Immunol. 1998;81:478-518.
18. Borres MP, Brakenhielm G, Irander K. How many teenagers think they have allergic rhinoconjunctivitis and what they do about it. Ann Allergy Asthma Immunol. 1997;78:29-34.
19. Heaton AH, Meltzer EO, Kaplan JG. The treatment of seasonal allergic rhinitis in managed care: the role of azelastine. In: Ovation Report on Cost-Effective Products. Highland Park, IL: Ovation Research Group; 1998:7-14.
20. Physician Survey sponsored by American College of Allergy, Asthma and Immunology; October 19-29, 2001. Available from: Harris Interactive Inc, Rochester, NY.
21. Wang D, Smitz J, De Waele M, Clement P. Effect of topical applications of budesonide and azelastine on nasal symptoms, eosinophil count and mediator release in atopic patients after nasal allergen challenge during the pollen season. Int Arch Allergy Immunol. 1997;114:185-192.
22. Berger WE, Schenkel EJ, Mansfield LE. Desloratadine Study Group. Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann Allergy Asthma Immunol. 2002;89:485-491.
23. Wilson AM, Haggart K, Sims EJ, Lipworth BJ. Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin Exp Allergy. 2002;32:1504-1509.
24. Yanai K, Okamura N, Tagawa M, Itoh M, Watanabe T. New findings in pharmacological effects induced by antihistamines: from PET studies to knock-out mice. Clin Exp Allergy. 1999;29(Suppl):29-36.